Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002236 · ClinicalTrials.gov registry record · NA
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00002236: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002236 is a NA study that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002236, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
Interventions
- DRUG Zidovudine
- DRUG Indinavir sulfate
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002236
The ClinicalTrials.gov registry entry for NCT00002236 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002236 about?
NCT00002236 is a clinical study titled "A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients". The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
What is the current status of trial NCT00002236?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants.
What interventions are being tested in trial NCT00002236?
The interventions under investigation include: Zidovudine (DRUG), Indinavir sulfate (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002236?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.